Articles From: BIOLASE Awarded Two New Patents to BioLineRx Reports Year End 2012 Financial Results


2013/5/15
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1017661&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE Awarded Two New Patents investment picks
2013/3/6
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=993717&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE CEO to Continue at Symbolic Annual Cash Salary of $1.00 investment picks
2013/2/28
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=991339&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE Declares Stock Dividend for 2013 First Quarter investment picks
2013/5/7
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1014810&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE Enters Affiliation Agreement With Sun Dental Laboratories, LLC investment picks
2013/4/17
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1008017&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE Enters Into Agreement for Lambda S.p.A. to Pay Royalties investment picks
2013/3/13
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=996205&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE Holds Annual Distributor Meeting at 35th IDS International Dental Show in Cologne, Germany investment picks
2013/2/7
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=983098&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE Issued Broad New Patent for Treating Eye Conditions, Including Presbyopia, Cataracts, and Glaucoma investment picks
2013/4/4
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1003575&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE Joins OSAP in Fight for Safe and Infection-Free Oral Healthcare investment picks
2013/2/26
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=990035&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE Launches Soft-Tissue Diode Laser for Veterinary Applications investment picks
2013/2/6
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=982605&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE Receives FDA Clearance for Its 940nm Diolase 10(TM) Diode Soft Tissue Laser for a Broad Spectrum of Medical Procedures investment picks
2013/5/8
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1014976&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE Receives FDA Clearance for Orthopedic and Podiatric WaterLase iPlus investment picks
2013/4/11
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1006122&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE Receives FDA Clearance for the EPIC 10S Soft Tissue Diode Laser for a Broad Spectrum of Medical Procedures investment picks
2013/2/12
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=984453&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE Recognized With "Best AEEDC Dubai Booth Activities Award" at Recent UAE Dental Conference & Arab Dental Exhibition investment picks
2013/3/6
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=993910&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE Reports 2012 Fourth Quarter, Year-End Results investment picks
2013/5/7
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1014773&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE Reports 2013 First Quarter Results investment picks
2013/4/30
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1012043&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE to Host First Quarter 2013 Results Conference Call and Webcast on May 7th at 4:30 P.M. EDT investment picks
2013/2/13
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=985070&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE to Host Fourth Quarter Financial Results Conference Call on March 6, 2013 investment picks
2013/2/14
http://media.marketwire.com/attachments/200709/365332_biologo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=985829&ProfileId=051205&sourceType=1 IRVINE, CA --
Sign-up for BIOLASE to Present at Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference investment picks
2013/2/6
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) , is proud to announce the worldwide release of the high performance ISOLATE II range of nucleic acid purification kits.
Sign-up for Bioline Launches ISOLATE II, a Precious Find for DNA and RNA Isolation investment picks
2013/2/13
BioLineRx Ltd.
Sign-up for BioLineRx Announces Closing of $8 Million Offering of American Depositary Shares investment picks
2013/2/6
BioLineRx Ltd.
Sign-up for BioLineRx Announces Offering of American Depositary Shares investment picks
2013/4/17
BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today positive Phase IIa results for BL-7040, an orally available drug for treating inflammatory bowel disease (IBD). The study showed that BL-7040 is safe and effective in treating ulcerative colitis, a form of IBD.
Sign-up for BioLineRx Announces Positive Phase II Results for BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease investment picks
2013/3/20
BioLineRx (NASDAQ: BLRX)  (TASE: BLRX), a biopharmaceutical development company, today announced that results from a pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, indicate that the trial would not meet the pre-specified primary efficacy endpoint.
Sign-up for BioLineRx Announces Results from Interim Analysis of Phase II/III CLARITY Trial of BL-1020 for Schizophrenia investment picks
2013/4/29
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV). The patient was enrolled at the Hôpital Cochin in Paris, France.
Sign-up for BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C investment picks
2013/5/17
BioLineRx Ltd.
Sign-up for BioLineRx Enters into “At-The-Market” Offering Agreement with Stifel, Nicolaus & Company investment picks
2013/2/4
BioLineRx Ltd.
Sign-up for BioLineRx Provides Clarification Regarding Interim Analysis of CLARITY Trial for BL-1020 investment picks
2013/3/13
BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today that it has received approval from the French regulatory authorities to commence a Phase I/II trial for BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV). The study is an open-label trial to evaluate the efficacy, safety and tolerability of BL-8020 in patients infected with HCV.
Sign-up for BioLineRx Receives Approval from French Regulatory Authorities to Commence a Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C investment picks
2013/4/10
BioLineRx (NASDAQ:BLRX) (TASE:BLRX), a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia (AML). The study is a multicenter, open-label study under an IND, designed to evaluate the safety and efficacy profile of repeated escalating doses of BL-8040 in adult subjects with relapsed/refractory AML.
Sign-up for BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial for BL-8040, for Treatment of Leukemia investment picks
2013/5/7
BioLineRx Ltd.
Sign-up for BioLineRx Reports First Quarter 2013 Results investment picks
2013/3/12
BioLineRx Ltd.
Sign-up for BioLineRx Reports Year End 2012 Financial Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: BIOLASE Awarded Two New Patents to BioLineRx Reports Year End 2012 Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity